Critical test evaluation of butamisole against gastrointestinal parasites of horses and ponies.
A critical test was performed to evaluate the anthelmintic properties of an injectable butamisole formulation and to compare the efficiency with that of a commercially available piperazine-thiabendazole anthelmintic. The test was done in 10 horses and 15 ponies with naturally acquired parasitic infections. Butamisole was administered at the dose level of 2.5 or 3.75 mg/kg of body weight by either subcutaneous or deep intramuscular injection. Given at the dose level of 2.5 mg/kg, butamisole was highly effective (99%) against Strongylus vulgaris and moderately effective (49%) against Parascaris equorum. At the 3.75 mg/kg dose rate, butamisole was highly effective against both S vulgaris (97%) and P equorum (94%). Butamisole had limited efficacy against other parasite species. Signs of toxicosis, long-term swelling of the injection sites, or tissue damage were not seen after injection.
D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use*; D006734:Horse Diseases / Q000188:drug therapy*; D006736:Horses; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D009349:Nematode Infections / Q000188:drug therapy / Q000662:veterinary*; D010879:Piperazines / Q000627:therapeutic use; D013319:Strongyle Infections, Equine / Q000188:drug therapy; D013827:Thiabendazole / Q000627:therapeutic use; D013844:Thiazoles / Q000008:administration & dosage / Q000627:therapeutic use
D000871:Anthelmintics; D007093:Imidazoles; D010879:Piperazines; D013844:Thiazoles; D013827:Thiabendazole; C020238:butamisole